AstraZeneca Cocktail Shows Promising Signs in the Treatment of COVID 19
AstraZeneca experimental COVID 19 cocktail drug has shown promising signs in the battle against COVID
A late-stage study has revealed that the drug reduced the risk of developing severe COVID-19 or death in symptomatic patients
The company will discuss the result with authorities with the hope of developing it as a therapy for people without a strong enough immune response to the vaccines
AstraZeneca has developed an experimental COVID 19 antibody-drug cocktail that is capable of reducing severe cases of the disease or death among patients who haven’t been hospitalized.
The drugmaker disclosed on Monday that the drug named AZD7442 has proven to help reduce the risk of developing severe COVID or death.
Vice President of the company Mene Pangalos said
“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,”
The company has disclosed that the data received from the experiment will be discussed with authorities.
Read also: Nigeria Receives 501,600 Doses of Vaccine
AstraZeneca has disclosed that the cocktail drug is also being developed as a therapy to protect people who don’t have a strong immune system against the vaccine.
The company is awaiting a response after requesting emergency approval from US regulators for the use of the emergency drug.